ERBB2 and breast cancer: The direct anti-tumor activity is not restricted to the triple-negative BC cell lines but also involves HER2+ HCC-1954 cells, CRC HT29, and glioblastoma U-373MG (data not shown), whereas HUVEC cells induced CD32-CR down-regulation.